Merrimack Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>MP</div>
As many rational traders are trying to avoid healthcare space, it makes sense to examine Merrimack Pharmaceuticals a little further and understand how it stands against DiaMedica Therapeutics and other similar entities. We are going to concentrate on some of the competitive aspects of both Merrimack and DiaMedica.
Published over a month ago
View all stories for Merrimack Pharmaceuticals | View All Stories
Will Merrimack Pharmaceuticals (NASDAQ:MACK) traders shift to DiaMedica (NASDAQ:DMAC)?
By analyzing existing forward indicators between Merrimack Pharmaceuticals and DiaMedica, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in DiaMedica with a short position in Merrimack Pharmaceuticals. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Merrimack Pharmaceuticals has an asset utilization ratio of 121.84 percent. This signifies that the company is making $1.22 for each dollar of assets. An increasing asset utilization means that Merrimack Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

How important is Merrimack Pharmaceuticals's Liquidity

Merrimack Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Merrimack Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Merrimack Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Merrimack Pharmaceuticals's total debt and its cash.

How Merrimack utilizes its cash?

To perform a cash flow analysis of Merrimack Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Merrimack Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Merrimack Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Merrimack Pharmaceuticals Net Cash Flow from Operations is decreasing as compared to previous years. The last year's value of Net Cash Flow from Operations was reported at (31.37 Million)

Breaking down the case for Merrimack Pharmaceuticals

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Now, let's check Merrimack Pharmaceuticals revenue. Based on the latest financial disclosure, Merrimack Pharmaceuticals reported 144.27 M of revenue. This is 98.11% lower than that of the Healthcare sector and 80.58% lower than that of the Biotechnology industry. The revenue for all United States stocks is 98.47% higher than that of the firm. As for DiaMedica Therapeutics we see revenue of 447.37 K, which is 99.94% lower than that of the Biotechnology

Merrimack144.27 Million
Sector742.91 Million
DiaMedica447,368
Merrimack
742.9 M
Sector
DiaMedica

Another 3 percent surge for Merrimack Pharmaceuticals

Value At Risk just dropped to -3.3, may signify upcoming price decrease. As of the 15th of August 2020, Merrimack Pharmaceuticals secures the Mean Deviation of 2.22, downside deviation of 2.48, and Risk Adjusted Performance of 0.0278. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Merrimack Pharmaceuticals, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Merrimack Pharmaceuticals, which can be compared to its peers in the industry. Please verify Merrimack Pharmaceuticals variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Merrimack Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 4.3 per share. Given that Merrimack Pharmaceuticals has jensen alpha of (0.028755), we recommend you to check Merrimack Pharmaceuticals's last-minute market performance to make sure the company can sustain itself at a future point.

Our Final Take On Merrimack Pharmaceuticals

Although some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Merrimack Pharmaceuticals may offer a potential longer-term growth to traders. To conclude, as of the 15th of August 2020, our primary 30 days 'Buy-Sell' recommendation on the firm is Strong Sell. However, we believe Merrimack Pharmaceuticals is undervalued with high probability of bankruptcy for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Merrimack Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com